

TSRI 609.1  
SN 09/581,044


application under 35 U.S.C. § 371 of copending International Application No. PCT/US98/25964, filed December 8, 1998 and published in English, which claims priority, under 35 U.S.C. § 119(e), from provisional application Serial No. 60/067,959, filed December 8, 1997, the disclosures of which are hereby incorporated by reference.

BEST AVAILABLE COPY

In the Claims:

Please cancel claim 23 without prejudice and replace claims 1 and 3 with the following further amended claims.

1. (twice amended) A protease inhibitor represented by the following structure:



wherein

$R_1$  is selected from the group consisting of hydrogen, carbobenzyloxy-, carbobenzyloxy-glycine-valine-, carbobenzyloxy-alanine-valine-, carbobenzyloxy-leucine-valine-, carbobenzyloxy-phenylalanine-valine-, carbobenzyloxy-serine-valine-, carbobenzyloxy-alanine-asparagine-, carbobenzyloxy-threonine-valine- and carbobenzyloxy-valine-valine-;

$R_2$  is selected from the group consisting of  $-\text{CH}_2\text{-Phenyl}$ , and  $-\text{CH}_2\text{-CH}(\text{CH}_3)_2$ ;

$R_3$  is selected from the group consisting of hydrogen, oxygen and hydroxyl;  $R_4$  is selected from the group consisting of hydrogen, oxygen and hydroxyl, wherein  $R_3$  and  $R_4$  are not both hydroxyl and wherein  $R_3$  and  $R_4$  are either not oxygen or are a single combined oxygen forming a carbonyl group;


TSRI 609.1  
SN 09/581,044

BEST AVAILABLE COPY

*F1 conclude*

$R_5$  is selected from the group consisting of hydrogen, and oxygen;  $R_6$  is selected from the group consisting of hydrogen, and oxygen, wherein  $R_5$  and  $R_6$  are either a single combined oxygen forming a carbonyl group or both separately hydrogen;


$R_7$  is a radical represented by the formula:



wherein  $R_8$  is a radical selected from the group consisting of  $-(H)_2$ , and  $-H(t\text{-Butyl})$ ; with a proviso that, if either  $R_3$  or  $R_4$  is hydroxyl, then  $R_1$  is neither hydrogen nor carbobenzyloxy-.

*F3*

3. (thrice amended) A stereochemically pure protease inhibitor represented by the following structure:



*Sub F3*

wherein

$R_1$  is a radical selected from the group consisting of carbobenzyloxy-glycine-valine-, carbobenzyloxy-alanine-valine-, carbobenzyloxy-leucine-valine-, carbobenzyloxy-phenylalanine-valine-, carbobenzyloxy-serine-valine-, carbobenzyloxy-threonine-valine-, carbobenzyloxy-alanine-asparagine- and carbobenzyloxy-valine-valine-; and

$R_2$  is a radical selected from the group consisting of  $-(H)_2$ , and  $-H(t\text{-Butyl})$ .